DiamiR receives funding to evaluate microRNA biomarkers for Alzheimer's disease

The National Institute on Aging of the National Institutes of Health has awarded DiamiR a Small Business Innovation Research grant to support further validation and development of the company's targeted diagnostic technology based on the analysis of brain-enriched microRNA biomarkers in plasma for early detection of Alzheimer's disease and mild cognitive impairment (MCI).

The award will provide DiamiR with approximately USD 1.5 million over 2 years. This award will also support the analysis of archived and prospectively collected plasma samples; the analysis will be conducted in collaboration with leading academic centers. This funding will also allow the company to conduct larger studies and to advance the development of its first test, CogniMIR, for early detection of MCI with the initial application in clinical trials support (DiamiR News Release).